Genmab A/S (GMAB) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Copenhagen, Denmark. 현재 CEO는 Jan van de Winkel.
GMAB 을(를) 보유 IPO 날짜 2009-06-01, 2,638 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $17.94B.
Genmab A/S is a Danish biopharmaceutical company founded in 1999 that develops antibody-based therapeutics for cancer and other serious diseases. The company's commercial portfolio includes DARZALEX (daratumumab) for multiple myeloma and other blood cancers, teprotumumab for thyroid eye disease, ofatumomab for chronic lymphocytic leukemia and multiple sclerosis, and amivantamab for gastric, esophageal, and lung cancers. Genmab maintains a robust pipeline of clinical and pre-clinical programs, including tisotumab vedotin for solid tumors, epcoritamab for lymphomas, and multiple early-stage candidates in Phase 2 development across oncology and other therapeutic areas. The company partners with leading pharmaceutical and biotech firms including Seagen, AbbVie, Janssen, BioNTech, and Novo Nordisk to advance its research and development efforts globally.
